Clovis Stock Analysis

CLVS -  USA Stock  

USD 5.06  0.24  4.98%

Clovis Oncology price fall over the last few months could raise concerns from retail investors as the firm it trading at a share price of 5.06 on 3,068,988 in volume. The company directors and management were not very successful in positioning the firm resources to exploit market volatility in July. However, diversifying your holdings with Clovis Oncology or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.39. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Clovis Oncology partners.
Continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Clovis Oncology stock analysis report makes it easy to digest most publicly released information about Clovis Oncology and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Clovis Stock analysis module also helps to analyze the Clovis Oncology price relationship with some important fundamental indicators such as market cap and management efficiency.

Clovis Stock Analysis Notes

About 50.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 3.64. Clovis Oncology had not issued any dividends in recent years. Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company was incorporated in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 429 people. For more info on Clovis Oncology please contact Patrick Mahaffy at 303 625-5000 or go to www.clovisoncology.com.

Clovis Oncology Quarterly Cost of Revenue

9.64 MillionShare

Clovis Oncology Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Clovis Oncology's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Clovis Oncology or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Clovis Oncology generates negative expected return over the last 90 days
Clovis Oncology has high historical volatility and very poor performance
Clovis Oncology has high likelihood to experience some financial distress in the next 2 years
Clovis Oncology has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 160.01 M. Net Loss for the year was (336.16 M) with profit before overhead, payroll, taxes, and interest of 128.39 M.
Clovis Oncology currently holds about 190.92 M in cash with (232.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83.
Clovis Oncology has a poor financial position based on the latest SEC disclosures
Latest headline from www.equities.com: Clovis Oncology falls 1.22 percent on Moderate Volume August 3 - Equities.com

Clovis Oncology Upcoming and Recent Events

Earnings reports are used by Clovis Oncology to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Clovis Oncology previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End22nd of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Clovis Largest EPS Surprises

Earnings surprises can significantly impact Clovis Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2013-08-01
2013-06-30-0.65-0.72-0.0710 
2021-05-05
2021-03-31-0.7183-0.640.078310 
2020-11-05
2020-09-30-0.9983-0.890.108310 
View All Earnings Estimates

Clovis Oncology SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Clovis Oncology prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Clovis Oncology investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Clovis Oncology specific information freely available to individual and institutional investors to make a timely investment decision.
13th of July 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
23rd of June 2021
Submission of Matters to a Vote of Security Holders
View
10th of June 2021
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Unclassified Corporate Event
View
17th of May 2021
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
View
5th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
12th of April 2021
Unclassified Corporate Event
View
23rd of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
16th of February 2021
Unclassified Corporate Event
View

Clovis Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 508.19 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Clovis Oncology's market, we take the total number of its shares issued and multiply it by Clovis Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Clovis Profitablity

Clovis Oncology's profitability indicators refer to fundamental financial ratios that showcase Clovis Oncology's ability to generate income relative to its revenue or operating costs. If, let's say, Clovis Oncology is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Clovis Oncology's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Clovis Oncology's profitability requires more research than a typical breakdown of Clovis Oncology's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (210.08) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (173.85) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.74.
Last ReportedProjected for 2021
Return on Investment(63.17) (68.16) 
Return on Average Assets(0.61) (0.66) 
Return on Average Equity 2.70  2.92 
Return on Invested Capital(0.45) (0.49) 
Return on Sales(2.06) (2.23) 

Management Efficiency

The entity has return on total asset (ROA) of (30.22) % which means that it has lost $30.22 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 7.97 %, meaning that it created $7.97 on every $100 dollars invested by stockholders. Clovis Oncology management efficiency ratios could be used to measure how well clovis oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of 08/05/2021, Return on Average Equity is likely to grow to 2.92, while Return on Investment is likely to drop (68.16) . Clovis Oncology Average Assets are relatively stable at the moment as compared to the past year. Clovis Oncology reported last year Average Assets of 607.15 Million. As of 08/05/2021, Tangible Asset Value is likely to grow to about 482.6 M, while Asset Turnover is likely to drop 0.22.
Last ReportedProjected for 2021
Book Value per Share(1.88) (1.93) 
Enterprise Value over EBIT(2.00) (2.16) 
Enterprise Value over EBITDA(2.52) (2.72) 
Price to Book Value(2.67) (2.88) 
Tangible Assets Book Value per Share 5.66  5.80 
Enterprise Value834.2 M1.2 B
Tangible Asset Value476.7 M482.6 M

Technical Drivers

As of the 5th of August, Clovis Oncology shows the risk adjusted performance of (0.038823), and Mean Deviation of 2.56. Clovis Oncology technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Clovis Oncology, which can be compared to its rivals. Please confirm Clovis Oncology coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Clovis Oncology is priced correctly, providing market reflects its regular price of 5.06 per share. Given that Clovis Oncology has jensen alpha of (0.22), we suggest you to validate Clovis Oncology's prevailing market performance to make sure the company can sustain itself at a future point.

Clovis Oncology Price Movement Analysis

The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Clovis Oncology middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Clovis Oncology. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Clovis Oncology Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Clovis Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Clovis Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Clovis Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Simantov Ronit over three weeks ago via Macroaxis 
Acquisition by Simantov Ronit of 83212 shares of Clovis Oncology subject to Rule 16b-3
Harding Thomas C over three weeks ago via Macroaxis 
Exercise or conversion by Harding Thomas C of tradable shares of Clovis Oncology subject to Rule 16b-3
Harding Thomas C over a month ago via Macroaxis 
Exercise or conversion by Harding Thomas C of tradable shares of Clovis Oncology subject to Rule 16b-3
Harding Thomas C over three months ago via Macroaxis 
Exercise or conversion by Harding Thomas C of 181 shares of Clovis Oncology subject to Rule 16b-3
Harding Thomas C over three months ago via Macroaxis 
Clovis Oncology exotic insider transaction detected
Harding Thomas C over three months ago via Macroaxis 
Sale by Harding Thomas C of 1987 shares of Clovis Oncology
Harding Thomas C over three months ago via Macroaxis 
Exercise or conversion by Harding Thomas C of tradable shares of Clovis Oncology subject to Rule 16b-3
Harding Thomas C over three months ago via Macroaxis 
Exercise or conversion by Harding Thomas C of 282 shares of Clovis Oncology subject to Rule 16b-3
Harding Thomas C over three months ago via Macroaxis 
Clovis Oncology exotic insider transaction detected
Harding Thomas C over six months ago via Macroaxis 
Exercise or conversion by Harding Thomas C of 7250 shares of Clovis Oncology subject to Rule 16b-3
Lindsey Rolfe over six months ago via Macroaxis 
Exercise or conversion by Lindsey Rolfe of 3438 shares of Clovis Oncology subject to Rule 16b-3
Lindsey Rolfe over six months ago via Macroaxis 
Exercise or conversion by Lindsey Rolfe of 17241 shares of Clovis Oncology subject to Rule 16b-3

Clovis Oncology Predictive Daily Indicators

Clovis Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Clovis Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Clovis Oncology Forecast Models

Clovis Oncology time-series forecasting models is one of many Clovis Oncology's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Clovis Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Clovis Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Clovis Oncology stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Clovis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Clovis Oncology. By using and applying Clovis Stock analysis, traders can create a robust methodology for identifying Clovis entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(2.01) (2.17) 
Gross Margin 0.75  0.79 
Profit Margin(2.24) (2.42) 
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company was incorporated in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 429 people.

Current Clovis Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Clovis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Clovis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
6.69Sell4Odds
Clovis Oncology current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Clovis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Clovis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Clovis Oncology, talking to its executives and customers, or listening to Clovis conference calls.
Clovis Analyst Advice Details

Clovis Stock Analysis Indicators

Clovis Oncology stock analysis indicators help investors evaluate how Clovis Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Clovis Oncology shares will generate the highest return on investment. By understating and applying Clovis Oncology stock analysis, traders can identify Clovis Oncology position entry and exit signals to maximize returns.
Quick Ratio1.25
Fifty Two Week Low4.0800
Revenue Growth-10.60%
Shares Short Prior Month30.46M
Average Daily Volume Last 10 Day2.81M
Average Daily Volume In Three Month5.94M
Shares Percent Shares Out29.47%
Gross Margins77.94%
Short Percent Of Float30.23%
Forward Price Earnings-4.05
Float Shares102.67M
Fifty Two Week High11.1000
Enterprise Value To Ebitda-4.14
Fifty Day Average5.5082
Two Hundred Day Average6.1729
Enterprise Value To Revenue6.99
Continue to Trending Equities. Note that the Clovis Oncology information on this page should be used as a complementary analysis to other Clovis Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Clovis Stock analysis

When running Clovis Oncology price analysis, check to measure Clovis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clovis Oncology is operating at the current time. Most of Clovis Oncology's value examination focuses on studying past and present price action to predict the probability of Clovis Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Clovis Oncology's price. Additionally, you may evaluate how the addition of Clovis Oncology to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
The market value of Clovis Oncology is measured differently than its book value, which is the value of Clovis that is recorded on the company's balance sheet. Investors also form their own opinion of Clovis Oncology's value that differs from its market value or its book value, called intrinsic value, which is Clovis Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clovis Oncology's market value can be influenced by many factors that don't directly affect Clovis Oncology underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clovis Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Clovis Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clovis Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.